SlideShare a Scribd company logo
1 of 8
Download to read offline
Italy Diabetes Market Report and Forecast
About IMARC
For more than 5 years, the International Market Analysis Research and Consulting Group has
been a leading advisor on management strategy and market research worldwide. We partner
with clients in all sectors and regions to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.


IMARC's information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company's expertise.


IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.




imarc©
About The Report
IMARC’s new report “Italy Diabetes Market Forecast 2011-2016” provides an analytical and
statistical insight into the Italian diabetes market. The report provides both current and
future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes
in Italy. The report has segmented the Italian diabetes market into two segments – Insulin and
the Oral Antidiabetics market. For each of the aforementioned categories, the report
provides historical and future market sales of key classes, key companies, key drugs and key
molecules.


The research study serves as an exceptional tool to understand the market trends,
therapeutic structure, competitive structure and the outlook of the Italian diabetes market
till 2016. This report can serve as an excellent guide for investors, researchers, consultants,
marketing strategists and all those who are planning to foray into the Italian diabetes market
in some form or the other.


Key Questions Answered in this Report:

   What is the size and demographical breakup of the diabetes population in Italy?
   What are the current and future diagnosis and drug treatment rates of diabetes in Italy?
   How has the diabetes market behaved since 2005 and what are the expected trends till
   2016?
   What has been the historical performance of the Italian Insulin market during 2005-2010
   and its outlook till 2016?
    What has been the performance of top classes, top players, top molecules and top drugs
   in the Insulin market during 2005-2010?
   What has been the historical performance of the Oral Antidiabetics market during 2005-
   2010 and its outlook till 2016?
    What has been the performance of top classes, top players, top molecules and top drugs
   in the Oral Antidiabetics market during 2005-2010?




imarc©
Why should you buy this report?

   Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in
   Italy and identify your potential patient pool.
   Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics
   market to identify potential classes, drugs, partners and competitors for market entry and
   expansion plans.
   Develop Investment strategies by identifying companies that have been the biggest
   winners and losers in the Italian Insulin and Oral Antidiabetics market.
   Gain an insight into future market events such as biosimilars and new product launches.


Classes Covered:
Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate
acting    Insulins,   Biguanides,   Glitazone   and   Biguanide   combinations,   Biguanide   and
Sulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1
Agonists,     Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations,
Glitazone and Sulphonylurea combinations, SGLT Inhibitors,         SGLT Inhibitor and Biguanide
combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.



Information Sources:
Information has been sourced from both primary and secondary sources:
         Primary sources include industry surveys and face to face/telephonic interviews with
         physicians and industry experts.
         Secondary sources include proprietary databases and search engines. These sources
         include company websites and reports, books, trade journals, magazines, white
         papers, Industry Portals, government sources and access to more than 4000 paid
         databases.


Forecasting Methodology:
IMARC generates its product and market forecasts utilizing its extensive database of
macroeconomic and sector specific data. The initial baseline forecast is generated with the
most recent market data. After an initial baseline forecast, all future macroeconomic and
sector specific events and assumptions are taken into account to generate the final forecast.




imarc©
Table of Contents


1     Executive Summary ---------------------------------------------------------------------------------------------------- 10

2     Epidemiology ------------------------------------------------------------------------------------------------------------- 12

    2.1     Total Diabetes Patients ----------------------------------------------------------------------------------------- 12
    2.2     Patients by Gender ----------------------------------------------------------------------------------------------- 13
    2.3     Patients by Age Group ------------------------------------------------------------------------------------------ 14
    2.4     Diagnosed and Drug Treated Population ----------------------------------------------------------------- 15

3     Market Dynamics -------------------------------------------------------------------------------------------------------- 16

    3.1     Diabetes Market --------------------------------------------------------------------------------------------------- 16
      3.1.1         Current Trends (2005–2010) ------------------------------------------------------------------------------ 16
      3.1.2         Market Forecast (2011-2016) ----------------------------------------------------------------------------- 17
    3.2     Insulin Market ------------------------------------------------------------------------------------------------------ 19
      3.2.1         Current Trends (2005-2010) ------------------------------------------------------------------------------ 19
          3.2.1.1      Market by Class ------------------------------------------------------------------------------------------- 20
          3.2.1.2      Market by Molecule -------------------------------------------------------------------------------------- 20
          3.2.1.3      Top Players ------------------------------------------------------------------------------------------------ 22
          3.2.1.4      Top Drugs -------------------------------------------------------------------------------------------------- 23
      3.2.2         Forecast (2011-2016) --------------------------------------------------------------------------------------- 24
    3.3     Oral Antidiabetics------------------------------------------------------------------------------------------------- 26
      3.3.1         Current Trends (2005-2010) ------------------------------------------------------------------------------ 26
          3.3.1.1      Market by Class ------------------------------------------------------------------------------------------- 28
          3.3.1.2      Top Players ------------------------------------------------------------------------------------------------ 30
          3.3.1.3      Top Drugs -------------------------------------------------------------------------------------------------- 31
      3.3.2         Forecast (2011-2016) --------------------------------------------------------------------------------------- 33




imarc©
List of Figures


Figure 2-1: Italy: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030 .................... 12
Figure 2-2: Italy: Breakup of Diabetes Patients by Gender (in 000’s), 2010, 2015, 2020, 2025 & 2030.... 13
Figure 2-3: Italy: Breakup of Diabetes Patients by Gender (in %), 2010, 2015, 2020, 2025 & 2030 ......... 13
Figure 2-4: Italy: Breakup of Diabetes Patients by Age Group (in 000’s), 2010, 2015, 2020, 2025 & 2030
.............................................................................................................................................................. 14
Figure 2-5: Italy: Breakup of Diabetes Patients by Age Group (in %), 2010, 2015, 2020, 2025 & 2030.... 14
Figure 2-6: Italy: Diagnosed & Drug Treated Population, (in %) 2010, 2015 & 2020 ............................... 15
Figure 3-1: Italy: Diabetes Market (in Million US$), 2005-2010 ............................................................... 16
Figure 3-2: Italy: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010 ............. 17
Figure 3-3: Italy: Diabetes Market Forecast (in Million US$), 2011-2016 ................................................. 17
Figure 3-4: Italy: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016 ............. 18
Figure 3-5: Italy: Insulin Market, (in Million US$), 2005-2010 .................................................................. 19
Figure 3-6: Italy: Breakup of Insulin Market by Class (in %), 2005-2010 ................................................. 20
Figure 3-7: Italy: Insulin Market: Share by Molecules (in %), 2005-2010 ................................................. 21
Figure 3-8: Italy: Insulin Market: Share of Key Players (in %), 2005-2010 ............................................... 22
Figure 3-9: Italy: Insulin Market: Share of Key Drugs (in %), 2005-2010 ................................................. 24
Figure 3-10: Italy: Insulin Market Forecast (in Million US$), 2011-2016 .................................................. 25
Figure 3-11: Italy: Oral Antidiabetics Market, (in Million US$), 2005-2010 ............................................... 27
Figure 3-12: Italy: Oral Antidiabetics Market: Share by Class (in %), 2005-2010 ..................................... 29
Figure 3-13: Italy: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010 ............................ 31
Figure 3-14: Italy: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010 .............................. 32
Figure 3-15: Italy-Oral Antidiabetics Market Forecast (in Million US$), 2011-2016 .................................. 34
Figure 3-16: Italy: Oral Antidiabetics Market Share by Class Forecast (in %), 2010-2016 ....................... 35




imarc©
List of Tables

Table 1-1: Italy: Diabetes Market: Market Definitions ................................................................................ 8
Table 2-1: Italy: Diagnosed & Drug Treated Population (in Millions), 2010, 2015 & 2020 ........................ 15
Table 3-1: Italy: Breakup of Insulin Market by Class (in Million US$), 2005-2010 .................................... 20
Table 3-2: Italy: Breakup of Insulin Market by Molecule (in Million US$), 2005-2010 ............................... 21
Table 3-3: Italy: Insulin Market: Sales of Key Players (in Million US$), 2005-2010 .................................. 22
Table 3-4: Italy: Insulin Market, Sales of Top Drugs (in Million US$), 2005-2010 .................................... 23
Table 3-5: Italy: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010 .......................... 28
Table 3-6: Italy: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010 ................. 30
Table 3-7: Italy: Oral Antidiabetics Market, Sales of Top Drugs (in Million US$), 2005-2010 ................... 31
Table 3-8: Italy: Oral Antidiabetics Market, New Drug Launches (2011-2016) ......................................... 33
Table 3-9: Italy: Oral Antidiabetics Market by Class Forecast, (in Million US$), 2010, 2013 & 2016 ........ 35




imarc©
Prices and Order Information




  Electronic Access         Electronic Access           CD-ROM Mail Delivery    Hard Copy Mail Delivery
(Single User License)      (Multi User License)         (Single User License)    (Single User License)

      US$ 750                    US$ 1300                     US$ 900                   US$ 900


  For more information visit: http://www.imarcgroup.com/italy-diabetes-market-forecast-2011-2016/


  To buy the complete report or to get a free sample:
  Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
  Email:sales@imarcgroup.com

More Related Content

Recently uploaded

Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Lviv Startup Club
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsP&CO
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxJemalSeid25
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakEditores1
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarNathanielSchmuck
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)tazeenaila12
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfHajeJanKamps
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfCharles Cotter, PhD
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinAnton Skornyakov
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentationbaron83
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfAnhNguyen97152
 

Recently uploaded (20)

Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizations
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptx
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerak
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry Webinar
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdf
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup Berlin
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
 

Italy Diabetes Market Report and Forecast

  • 2. About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results. imarc©
  • 3. About The Report IMARC’s new report “Italy Diabetes Market Forecast 2011-2016” provides an analytical and statistical insight into the Italian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in Italy. The report has segmented the Italian diabetes market into two segments – Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules. The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Italian diabetes market till 2016. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Italian diabetes market in some form or the other. Key Questions Answered in this Report: What is the size and demographical breakup of the diabetes population in Italy? What are the current and future diagnosis and drug treatment rates of diabetes in Italy? How has the diabetes market behaved since 2005 and what are the expected trends till 2016? What has been the historical performance of the Italian Insulin market during 2005-2010 and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010? What has been the historical performance of the Oral Antidiabetics market during 2005- 2010 and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010? imarc©
  • 4. Why should you buy this report? Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in Italy and identify your potential patient pool. Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans. Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Italian Insulin and Oral Antidiabetics market. Gain an insight into future market events such as biosimilars and new product launches. Classes Covered: Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate acting Insulins, Biguanides, Glitazone and Biguanide combinations, Biguanide and Sulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations, Glitazone and Sulphonylurea combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes. Information Sources: Information has been sourced from both primary and secondary sources: Primary sources include industry surveys and face to face/telephonic interviews with physicians and industry experts. Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases. Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast. imarc©
  • 5. Table of Contents 1 Executive Summary ---------------------------------------------------------------------------------------------------- 10 2 Epidemiology ------------------------------------------------------------------------------------------------------------- 12 2.1 Total Diabetes Patients ----------------------------------------------------------------------------------------- 12 2.2 Patients by Gender ----------------------------------------------------------------------------------------------- 13 2.3 Patients by Age Group ------------------------------------------------------------------------------------------ 14 2.4 Diagnosed and Drug Treated Population ----------------------------------------------------------------- 15 3 Market Dynamics -------------------------------------------------------------------------------------------------------- 16 3.1 Diabetes Market --------------------------------------------------------------------------------------------------- 16 3.1.1 Current Trends (2005–2010) ------------------------------------------------------------------------------ 16 3.1.2 Market Forecast (2011-2016) ----------------------------------------------------------------------------- 17 3.2 Insulin Market ------------------------------------------------------------------------------------------------------ 19 3.2.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 19 3.2.1.1 Market by Class ------------------------------------------------------------------------------------------- 20 3.2.1.2 Market by Molecule -------------------------------------------------------------------------------------- 20 3.2.1.3 Top Players ------------------------------------------------------------------------------------------------ 22 3.2.1.4 Top Drugs -------------------------------------------------------------------------------------------------- 23 3.2.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 24 3.3 Oral Antidiabetics------------------------------------------------------------------------------------------------- 26 3.3.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 26 3.3.1.1 Market by Class ------------------------------------------------------------------------------------------- 28 3.3.1.2 Top Players ------------------------------------------------------------------------------------------------ 30 3.3.1.3 Top Drugs -------------------------------------------------------------------------------------------------- 31 3.3.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 33 imarc©
  • 6. List of Figures Figure 2-1: Italy: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030 .................... 12 Figure 2-2: Italy: Breakup of Diabetes Patients by Gender (in 000’s), 2010, 2015, 2020, 2025 & 2030.... 13 Figure 2-3: Italy: Breakup of Diabetes Patients by Gender (in %), 2010, 2015, 2020, 2025 & 2030 ......... 13 Figure 2-4: Italy: Breakup of Diabetes Patients by Age Group (in 000’s), 2010, 2015, 2020, 2025 & 2030 .............................................................................................................................................................. 14 Figure 2-5: Italy: Breakup of Diabetes Patients by Age Group (in %), 2010, 2015, 2020, 2025 & 2030.... 14 Figure 2-6: Italy: Diagnosed & Drug Treated Population, (in %) 2010, 2015 & 2020 ............................... 15 Figure 3-1: Italy: Diabetes Market (in Million US$), 2005-2010 ............................................................... 16 Figure 3-2: Italy: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010 ............. 17 Figure 3-3: Italy: Diabetes Market Forecast (in Million US$), 2011-2016 ................................................. 17 Figure 3-4: Italy: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016 ............. 18 Figure 3-5: Italy: Insulin Market, (in Million US$), 2005-2010 .................................................................. 19 Figure 3-6: Italy: Breakup of Insulin Market by Class (in %), 2005-2010 ................................................. 20 Figure 3-7: Italy: Insulin Market: Share by Molecules (in %), 2005-2010 ................................................. 21 Figure 3-8: Italy: Insulin Market: Share of Key Players (in %), 2005-2010 ............................................... 22 Figure 3-9: Italy: Insulin Market: Share of Key Drugs (in %), 2005-2010 ................................................. 24 Figure 3-10: Italy: Insulin Market Forecast (in Million US$), 2011-2016 .................................................. 25 Figure 3-11: Italy: Oral Antidiabetics Market, (in Million US$), 2005-2010 ............................................... 27 Figure 3-12: Italy: Oral Antidiabetics Market: Share by Class (in %), 2005-2010 ..................................... 29 Figure 3-13: Italy: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010 ............................ 31 Figure 3-14: Italy: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010 .............................. 32 Figure 3-15: Italy-Oral Antidiabetics Market Forecast (in Million US$), 2011-2016 .................................. 34 Figure 3-16: Italy: Oral Antidiabetics Market Share by Class Forecast (in %), 2010-2016 ....................... 35 imarc©
  • 7. List of Tables Table 1-1: Italy: Diabetes Market: Market Definitions ................................................................................ 8 Table 2-1: Italy: Diagnosed & Drug Treated Population (in Millions), 2010, 2015 & 2020 ........................ 15 Table 3-1: Italy: Breakup of Insulin Market by Class (in Million US$), 2005-2010 .................................... 20 Table 3-2: Italy: Breakup of Insulin Market by Molecule (in Million US$), 2005-2010 ............................... 21 Table 3-3: Italy: Insulin Market: Sales of Key Players (in Million US$), 2005-2010 .................................. 22 Table 3-4: Italy: Insulin Market, Sales of Top Drugs (in Million US$), 2005-2010 .................................... 23 Table 3-5: Italy: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010 .......................... 28 Table 3-6: Italy: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010 ................. 30 Table 3-7: Italy: Oral Antidiabetics Market, Sales of Top Drugs (in Million US$), 2005-2010 ................... 31 Table 3-8: Italy: Oral Antidiabetics Market, New Drug Launches (2011-2016) ......................................... 33 Table 3-9: Italy: Oral Antidiabetics Market by Class Forecast, (in Million US$), 2010, 2013 & 2016 ........ 35 imarc©
  • 8. Prices and Order Information Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery (Single User License) (Multi User License) (Single User License) (Single User License) US$ 750 US$ 1300 US$ 900 US$ 900 For more information visit: http://www.imarcgroup.com/italy-diabetes-market-forecast-2011-2016/ To buy the complete report or to get a free sample: Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) Email:sales@imarcgroup.com